Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Gonzalez (HCQ)
 
NCT04391127
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
33/37 inconclusive
    HYCOVID
     
    NCT04325893
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
    124/123 inconclusive
    • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    ORCHID
     
    NCT04332991
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
    242/237 inconclusive
    • inconclusive 2 % increase in clinical improvement,clinical improvement (14-day) (PE) with a high degree of certainty due to low risk of bias
    TEACH
     
    NCT04369742
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
    67/61 inconclusive
    • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    HYDRA (Hernandez-Cardenas)
     
    NCT04315896
    RCThydroxychloroquineplaceboCOVID-19 severe or criticallysome concern
    106/108 inconclusive
    • inconclusive 20 % decrease in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).